The phosphorylation of Erk has been demonstrated to correlate with the activity of CYH33 against breast cancer [25], ESCC [36] and HNSCC, but the precise mechanisms underlying how PI3Kα inhibitors suppressed Erk phosphorylation remained unclear. This evidence concerns the gene MAPK1 and breast carcinoma.